A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.

doi:10.1158/1078-0432.CCR-13-2200

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2014

Angevin Eric, Tabernero Josep, Elez Elena, Cohen Steven J, Bahleda Rastilav, van Laethem Jean-Luc, Ottensmeier Christian, Lopez-Martin Jose A, Clive Sally, Joly Florence, Ray-Coquard Isabelle, Dirix Luc, Machiels Jean-Pascal, Steven Neil, Reddy Manjula, Hall Brett, Puchalski Thomas A, Bandekar Rajesh, van de Velde Helgi, Tromp Brenda, Vermeulen Jessica, Kurzrock Razelle

Abstract excerpt

PURPOSE: This phase I/II study evaluated safety, efficacy, and pharmacokinetics of escalating, multiple doses of siltuximab, a chimeric anti-interleukin (IL)-6 monoclonal antibody derived from a new Chinese hamster ovary (CHO) cell line in patients with advanced/refractory solid tumors. EXPERIMENTAL DESIGN: In the phase I dose-escalation cohorts, 20 patients with advanced/refractory solid tumors received...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CHO Cells

Share to Cricetulus

Share to Fatigue

Share to Interleukin-6

Share to Metabolic Clearance Rate

Share to Nausea

Share to Neutropenia

Source

Open in PubMed

Identifiers

PMID: 24563479
DOI: 10.1158/1078-0432.CCR-13-2200

Genes

KRAS
EGF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.PMID 24563479Read ↗

Phase 1 Dose Escalation Study of Seribantumab (MM-121), an anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid TumorsSemantic proximity Read ↗

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid TumorsSemantic proximity Read ↗

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.Semantic proximity Read ↗

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemiaSemantic proximity Read ↗

Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.Semantic proximity Read ↗

A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.Semantic proximity Read ↗

A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.Semantic proximity Read ↗

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumoursSemantic proximity Read ↗

Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: Results of a first-in-human Phase 1 trialSemantic proximity Read ↗

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.Semantic proximity Read ↗

GX-I7(rhIL-7-hyFc, efineptakin alfa), a long-acting IL-7, safely and effectively increased peripheral CD8<sup>+</sup>and CD4<sup>+</sup>T cells and TILs in patients with solid tumorsSemantic proximity Read ↗

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.